|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
CN106267189B
(zh)
|
2010-10-06 |
2021-02-26 |
瑞泽恩制药公司 |
含有抗白介素-4受体(il-4r)的抗体的稳定制剂
|
|
AU2012210481B2
(en)
|
2011-01-28 |
2017-05-18 |
Sanofi Biotechnology |
Pharmaceutical compositions comprising human antibodies to PCSK9
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
PH12014500342B1
(en)
|
2011-09-16 |
2019-06-14 |
Regeneron Pharma |
METHODS FOR REDUCING LIPOPROTEIN (a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
|
|
KR20210021112A
(ko)
|
2011-11-18 |
2021-02-24 |
리제너론 파마슈티칼스 인코포레이티드 |
폴리머 단백질 미립자
|
|
CA2861062A1
(en)
|
2012-01-23 |
2013-08-01 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ang2 antibodies
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US20140004131A1
(en)
*
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR092325A1
(es)
*
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
BR112015003590A8
(pt)
|
2012-08-21 |
2017-10-31 |
Sanofi Sa |
Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
SG10201701798TA
(en)
|
2012-09-07 |
2017-04-27 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
RU2015119547A
(ru)
*
|
2012-10-25 |
2016-12-20 |
МЕДИММЬЮН, ЭлЭлСи |
Стабильный низковязкий состав с антителом
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI633891B
(zh)
|
2013-06-04 |
2018-09-01 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
|
|
AU2014274844B2
(en)
|
2013-06-07 |
2019-11-28 |
Regeneron Pharmaceuticals, Inc. |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
AU2014284235C1
(en)
*
|
2013-06-21 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating nasal polyposis by administering an IL-4R antagonist
|
|
TWI634900B
(zh)
*
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
EP3036543B1
(en)
|
2013-08-23 |
2019-06-19 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
TWI670077B
(zh)
|
2013-11-12 |
2019-09-01 |
賽諾菲生物技術公司 |
使用ｐｃｓｋ９抑制劑之給藥療程
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
RU2704999C2
(ru)
|
2014-02-28 |
2019-11-01 |
Ридженерон Фармасьютикалз, Инк. |
Способ лечения кожной инфекции путем введения антагониста il-4r
|
|
CN107206068A
(zh)
|
2014-07-16 |
2017-09-26 |
赛诺菲生物技术公司 |
用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
|
|
KR20170044739A
(ko)
*
|
2014-09-03 |
2017-04-25 |
메디뮨 리미티드 |
안정한 항-ｉｌ-4ｒ-알파 항체 제형
|
|
IL294554B2
(en)
*
|
2014-11-14 |
2023-11-01 |
Regeneron Pharma |
Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist
|
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
|
WO2017143270A1
(en)
|
2016-02-19 |
2017-08-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
|
|
US11390669B2
(en)
|
2016-04-27 |
2022-07-19 |
Abbvie, Inc. |
Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
|
|
CN107474134B
(zh)
|
2016-06-08 |
2021-07-27 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
EP3506931B1
(en)
|
2016-09-01 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an il-4r antagonist
|
|
CN118203659A
(zh)
|
2016-09-22 |
2024-06-18 |
瑞泽恩制药公司 |
用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
|
|
IL266640B
(en)
|
2016-11-29 |
2022-09-01 |
Regeneron Pharma |
A pharmaceutical composition for averting opioid addiction
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
US11352417B2
(en)
|
2016-12-22 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
WO2018142514A1
(ja)
*
|
2017-02-01 |
2018-08-09 |
協和発酵キリン株式会社 |
ダルベポエチンを含む液体医薬組成物
|
|
CN110913900A
(zh)
|
2017-02-01 |
2020-03-24 |
耶鲁大学 |
利尿剂抵抗的治疗
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CA3067847A1
(en)
|
2017-07-06 |
2019-01-10 |
Regeneron Pharmaceuticals, Inc. |
Cell culture process for making a glycoprotein
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
CA3079946A1
(en)
|
2017-10-30 |
2019-05-09 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
JP7321159B2
(ja)
|
2017-12-22 |
2023-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
薬剤生成物不純物を特性決定するためのシステム及び方法
|
|
MA51584A
(fr)
|
2018-01-05 |
2020-11-11 |
Corvidia Therapeutics Inc |
Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression
|
|
SG11202005235WA
(en)
|
2018-01-31 |
2020-07-29 |
Regeneron Pharma |
System and method for characterizing size and charge variant drug product impurities
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
MX2020009696A
(es)
|
2018-03-19 |
2020-10-07 |
Regeneron Pharma |
Ensayos de electroforesis capilar de microchip y reactivos.
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
SG11202009371WA
(en)
|
2018-05-13 |
2020-10-29 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r inhibitor
|
|
CA3108697A1
(en)
|
2018-08-10 |
2020-02-13 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
|
|
US11358984B2
(en)
|
2018-08-27 |
2022-06-14 |
Regeneran Pharmaceuticals, Inc. |
Use of Raman spectroscopy in downstream purification
|
|
MX2021002281A
(es)
|
2018-08-30 |
2021-05-27 |
Regeneron Pharma |
Metodos para caracterizar complejos proteicos.
|
|
CN113056482A
(zh)
*
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CA3118144A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
US12216129B2
(en)
|
2018-11-09 |
2025-02-04 |
Ajou University Industry-Academic Cooperation Foundation |
Human antibody having high affinity to human IL-4 receptor alpha
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
CN113272651B
(zh)
|
2019-01-16 |
2023-06-16 |
瑞泽恩制药公司 |
鉴别蛋白质中的游离巯基的方法
|
|
PE20212185A1
(es)
|
2019-02-18 |
2021-11-11 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos
|
|
JP7548924B2
(ja)
|
2019-03-06 |
2024-09-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
|
|
CN111686247B
(zh)
*
|
2019-03-13 |
2022-07-29 |
苏州康乃德生物医药有限公司 |
包含人白介素-4受体α的抗体的液体组合物
|
|
TW202519263A
(zh)
*
|
2019-03-21 |
2025-05-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
|
PH12021552123A1
(en)
|
2019-03-21 |
2022-08-22 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
EP3962515A1
(en)
|
2019-05-01 |
2022-03-09 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-33 antagonist
|
|
KR20220007586A
(ko)
|
2019-05-13 |
2022-01-18 |
리제너론 파마슈티칼스 인코포레이티드 |
개선된 경쟁적 리간드 결합 검정
|
|
US12398212B2
(en)
|
2019-07-16 |
2025-08-26 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
|
AU2020326713A1
(en)
|
2019-08-05 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
CN114173819A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
|
|
EP4034870B1
(en)
|
2019-09-24 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
KR20220104797A
(ko)
|
2019-11-25 |
2022-07-26 |
리제너론 파마슈티칼스 인코포레이티드 |
비수성 에멀전을 이용한 지속 방출 제형
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
AU2020399975A1
(en)
|
2019-12-09 |
2022-07-28 |
Sanofi Biotechnology |
Methods for treating digitally-identified IL-4/IL-13 related disorders
|
|
AU2020415382A1
(en)
|
2019-12-23 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing allergic asthma by administering an IL-33 antagonist and/or an IL-4R antagonist
|
|
JP7342279B2
(ja)
|
2020-01-21 |
2023-09-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
グリコシル化タンパク質の電気泳動のための脱グリコシル化方法
|
|
BR112022016345A2
(pt)
*
|
2020-02-21 |
2022-12-20 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica contendo anticorpo anti-il-4r e uso da mesma
|
|
IL296214A
(en)
|
2020-03-27 |
2022-11-01 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
BR112022022235A2
(pt)
|
2020-05-22 |
2023-03-28 |
Regeneron Pharma |
Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
|
|
CN113797331A
(zh)
*
|
2020-06-16 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种稳定的抗IL-4Rα单克隆抗体液体制剂
|
|
KR20230035595A
(ko)
*
|
2020-07-08 |
2023-03-14 |
리제너론 파아마슈티컬스, 인크. |
항-ctla-4 항체를 함유하는 안정화된 제형
|
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
|
EP4225436A1
(en)
|
2020-10-05 |
2023-08-16 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
WO2022133135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
CA3204515A1
(en)
|
2021-01-08 |
2022-07-14 |
Jamie M. Orengo |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
EP4281542A1
(en)
|
2021-01-20 |
2023-11-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
|
WO2022187323A1
(en)
|
2021-03-03 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
CA3208011A1
(en)
|
2021-03-17 |
2022-09-22 |
Sarah Harris |
Methods of treating atopic dermatitis with anti il-13 antibodies
|
|
KR20230162932A
(ko)
|
2021-03-26 |
2023-11-29 |
리제너론 파아마슈티컬스, 인크. |
혼합 프로토콜 개발을 위한 방법 및 시스템
|
|
TW202304507A
(zh)
*
|
2021-04-02 |
2023-02-01 |
美商再生元醫藥公司 |
含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
|
|
CA3220848A1
(en)
|
2021-06-01 |
2022-12-08 |
Timothy Riehlman |
Microchip capillary electrophoresis assays and reagents
|
|
IL310362A
(en)
|
2021-07-26 |
2024-03-01 |
Sanofi Biotechnology |
Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
|
|
KR20240049351A
(ko)
|
2021-08-23 |
2024-04-16 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
TW202313692A
(zh)
*
|
2021-08-26 |
2023-04-01 |
大陸商正大天晴藥業集團股份有限公司 |
抗ｉｌ４ｒ抗體的藥物組成物及其用途
|
|
WO2023039457A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
|
|
CA3232463A1
(en)
*
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
CA3230985A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Ph meter calibration and correction
|
|
AU2022360838A1
(en)
|
2021-10-07 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
WO2023069976A1
(en)
|
2021-10-20 |
2023-04-27 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
KR20240097864A
(ko)
|
2021-10-26 |
2024-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
|
|
US20250011408A1
(en)
|
2021-11-19 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
MX2024006053A
(es)
|
2021-12-30 |
2024-07-29 |
Regeneron Pharma |
Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13.
|
|
US20230296559A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
EP4514849A1
(en)
|
2022-04-27 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
AU2023263975A1
(en)
*
|
2022-05-02 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-interleukin-4 receptor (il-4r) antibody formulations
|
|
WO2024011251A1
(en)
|
2022-07-08 |
2024-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
|
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
WO2024097714A1
(en)
|
2022-11-01 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
|
JP2025541690A
(ja)
|
2022-11-23 |
2025-12-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによる、骨成長を改善するための方法
|
|
KR20250124178A
(ko)
|
2022-12-16 |
2025-08-19 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템
|
|
TW202445135A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
液態蛋白質組成物穩定性之建模方法
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240255519A1
(en)
|
2023-02-01 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
TW202502819A
(zh)
|
2023-03-22 |
2025-01-16 |
法商賽諾菲生物技術公司 |
藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
|
|
US20240350626A1
(en)
|
2023-03-27 |
2024-10-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
|
|
WO2024199665A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
CN119215163A
(zh)
*
|
2023-06-30 |
2024-12-31 |
百奥泰生物制药股份有限公司 |
抗IL-4Rα抗体制剂及其制备方法和应用
|
|
WO2025017034A1
(en)
|
2023-07-17 |
2025-01-23 |
Formycon Ag |
Stable liquid antibody formulation for dupilumab
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
WO2025072597A2
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
AR134008A1
(es)
|
2023-10-02 |
2025-11-26 |
Regeneron Pharma |
Sistema de seguridad de dispositivo de administración de fármaco
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
TW202535934A
(zh)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
利用應力來降低脂酶活性的方法
|
|
WO2025116640A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
|
|
WO2025116648A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
|
|
WO2025116637A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 액상 제형
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
EP4623903A1
(en)
|
2024-03-28 |
2025-10-01 |
Fresenius Kabi Deutschland GmbH |
Pharmaceutical composition comprising dupilumab
|
|
US20250388685A1
(en)
|
2024-04-15 |
2025-12-25 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
CN118105485B
(zh)
*
|
2024-04-26 |
2024-09-03 |
湖南麦济生物技术有限公司 |
一种稳定的抗人IL-4Rα单克隆抗体制剂
|
|
WO2025247342A1
(zh)
*
|
2024-05-30 |
2025-12-04 |
重庆智翔金泰生物制药股份有限公司 |
包含抗il-4r抗体的药物组合物
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|